D<p> = patients 15, 39, 41, 44 and 61.</p><p><i>JAK2</i>LOH = loss of heterozygosity on the <i>JAK2</i> region, <i>JAK2</i>ROH = retention of heterozygosity on the <i>JAK2</i> region. MPN = myeloproliferative neoplasm.</p
Abstract Background JAK2V617F is found in the majority of patients with Ph- myeloproliferative neopl...
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the o...
In a retrospective single center study we determined the time course of the JAK2-V617F or JAK2 exon ...
A<p> = patient (pt) 5, 7, 9, 10, 11 and 12,</p>B<p> = pt 3*, <sup>C</sup> = pt 1, 2 and 6**.</p>*...
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an onco...
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an onco...
Myeloproliferative neoplasms and myelodysplastic/ myeloproliferative neoplasms are heterogeneous dis...
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, poly...
<p>SNP-A based karyotypic analysis on chromosome 9 for (A) a patient heterozygous for the JAK2 V617F...
Objective: Detection of MPL and JAK2 exon12 gene mutation in myeloproliferative neoplasms (MPN) in J...
Mutations in JAK2, MPL and CALR are highly relevant to the Philadelphia chromosome (Ph)-negative mye...
Objective/backgroundMyeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow stem ce...
Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V...
JAK2 (V617F) is associated with a genetic predisposition to its acquisition, as it is preferentially...
<div><p>Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythem...
Abstract Background JAK2V617F is found in the majority of patients with Ph- myeloproliferative neopl...
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the o...
In a retrospective single center study we determined the time course of the JAK2-V617F or JAK2 exon ...
A<p> = patient (pt) 5, 7, 9, 10, 11 and 12,</p>B<p> = pt 3*, <sup>C</sup> = pt 1, 2 and 6**.</p>*...
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an onco...
During tumor development, loss of heterozygosity (LOH) often occurs. When LOH is preceded by an onco...
Myeloproliferative neoplasms and myelodysplastic/ myeloproliferative neoplasms are heterogeneous dis...
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, poly...
<p>SNP-A based karyotypic analysis on chromosome 9 for (A) a patient heterozygous for the JAK2 V617F...
Objective: Detection of MPL and JAK2 exon12 gene mutation in myeloproliferative neoplasms (MPN) in J...
Mutations in JAK2, MPL and CALR are highly relevant to the Philadelphia chromosome (Ph)-negative mye...
Objective/backgroundMyeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow stem ce...
Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V...
JAK2 (V617F) is associated with a genetic predisposition to its acquisition, as it is preferentially...
<div><p>Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythem...
Abstract Background JAK2V617F is found in the majority of patients with Ph- myeloproliferative neopl...
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the o...
In a retrospective single center study we determined the time course of the JAK2-V617F or JAK2 exon ...